Skip to main content
SpringerLink
Log in

De la bonne prise en charge des poussées graves de RCH

  • Chapter
Post’U FMC-HGE

  • 167 Accesses

Résumé

  • Connaître les critères de définition et de diagnostic d’une colite grave; Connaître les modalités des différentes techniques thérapeutiques, leurs indications, leur surveillance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Goligher JC, de Dombal FT, Graham NG, Watkinson G. Early surgery in the management of severe ulcerative colitis. Br Med J 1967;3(559):193–5.

    Article  PubMed  CAS  Google Scholar 

  2. Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008;134:680–7.

    Article  PubMed  Google Scholar 

  3. Kornbluth A, Sachar DB. Ulcerative colitis guidelines in adults (update): American College of Gastroenterology. Practice parameters committee. Am J Gastro 2004; 1371–85.

    Google Scholar 

  4. Ho GT, Mowat C, Goddard CJR, Fennell JM, Shah NB, Prescott RJ, Satsangi J. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second line therapy or surgery. Alim Pharmacol Ther 2004; 19:1079–87.

    Article  CAS  Google Scholar 

  5. Aceituno M, Garcia Planella E, Heredia C, Zabana Y, Feu F, Domenech E, Gassull MA, Panes J. Steroid-refractory Ulcerative Colitis: Predictive Factors of Response to Cyclosporine and Validation in an Independent Cohort. Infl Bowel Dis 2008;14:347–52.

    Article  Google Scholar 

  6. Järnerot G, Hertervig E, Friis-Liby IL, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis. Randomised placebo controlled study. Gastroenterology 2005;128:1805–11.

    Article  PubMed  CAS  Google Scholar 

  7. Travis SPL, Stange EF, Lémann M, et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohn Colitis 2008;2:24–62.

    Article  Google Scholar 

  8. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955;2: 1041–8.

    Article  PubMed  CAS  Google Scholar 

  9. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067–70.

    Article  PubMed  CAS  Google Scholar 

  10. Truelove SC, Willoughby CP, Lee EG, Kettlewell MGW. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978;2: 1086–8.

    Article  PubMed  CAS  Google Scholar 

  11. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103–10.

    Article  PubMed  CAS  Google Scholar 

  12. Gustavsson A, Halfvarson J, Magnuson A, Sandberg-Gertz’en H, Tysk C, Järnerot G. Long term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol 2007; 102:2513–9.

    Article  PubMed  Google Scholar 

  13. Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990;12: 40–1.

    Article  PubMed  CAS  Google Scholar 

  14. Dickinson RJ, O’Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985;26:1380–4.

    Article  PubMed  CAS  Google Scholar 

  15. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210–2.

    Article  PubMed  CAS  Google Scholar 

  16. McIntyre PB, Powell-Tuck J, Wood SR, Lennard-Jones JE, Lerebours E, Hecketsweiler P, et al. Controlled trial of bowel rest in the treatment of severe ulcerative colitis. Gut 1986;27:481–5.

    Article  PubMed  CAS  Google Scholar 

  17. Dickinson RJ, Ashton MG, Axon ATR, Smith RC, Yeung CK, Hill GL. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980; 79:1198–1204.

    Google Scholar 

  18. Bouhnik Y, Alvès A, Beau P, Carbonnel F, Lévy P. Traitement des colites aiguës graves. Gastroenterol Clin Biol 2004; 28:984–91.

    PubMed  Google Scholar 

  19. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in ulcerative colitis. Gut 1996;38: 905–10.

    Article  PubMed  CAS  Google Scholar 

  20. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330: 1841–5.

    Article  PubMed  CAS  Google Scholar 

  21. D’Haens G, Lemmens L, Hiele L, et al. Intravenous cyclosporin versus corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323–9.

    Article  PubMed  Google Scholar 

  22. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005;1:CD004277.

    PubMed  Google Scholar 

  23. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Infl Bowel Dis 1995;1:48–63.

    Article  Google Scholar 

  24. Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short term and long term responses. Dig Dis Sci 1996;41: 2471–6.

    Article  PubMed  CAS  Google Scholar 

  25. Stack WA, Long RG, Hawkey CJ. Short-and long-term outcome of patients treated with cyclosporine for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998;12:973–8.

    Article  PubMed  CAS  Google Scholar 

  26. Wenzl HH, Petritsch W, Aichbichler BW, Hinterleitner TA, Fleischmann G, Krejs GJ. Short-term efficacy and long-term outcome of cyclosporine treatment in patients with severe ulcerative colitis. Z Gastroenterol 1998;36:287–93.

    PubMed  CAS  Google Scholar 

  27. Reimund JM, Duclos B, Baumann R. Traitement des formes sévères de rectocolite hémorragique par la cyclosporine. A propos de 7 cas. Ann Med Interne 1997;148:527–9.

    CAS  Google Scholar 

  28. Van Gossum A, Schmit A, Adler M, et al. Short-and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastroenterol Belg 1997;60:197–200.

    PubMed  Google Scholar 

  29. Santos J, Baudet S, Casellas F, Guarner L, Vilaseca J, Malagelada JR. Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis. J Clin Gastroenterol 1995; 20:285–9.

    PubMed  CAS  Google Scholar 

  30. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis. A five-year experience. Am J Gastroenterol 1999;94:1587–92.

    Article  PubMed  CAS  Google Scholar 

  31. Fernández-Bañares F, Bertrán X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91:2498–9.

    PubMed  Google Scholar 

  32. Moskovitz DN, Van Assche G, Maenhout B, Arts J, Vermeire S, Rutgeerts P. Colectomy rates after cyclosporine induced remission: 7 years experience in ulcerative colitis. Clin Gastroenterol Hepatol 2006;4: 760–5.

    Article  PubMed  CAS  Google Scholar 

  33. van Assche G, D’Haens G, Noman M et al. Randomized double blind comparison of 4 mg/kg vs 2 mg/kg ciclosporine in severe ulcerative colitis. Gastroenterology 2003;125: 1025–32.

    Article  PubMed  Google Scholar 

  34. De Saussure P, Soravia C, Morel P, Hadengue A. Low dose oral microemulsion ciclosporine for severe refractory colitis. Alim Pharmacol Ther 2005;22:203–8.

    Article  CAS  Google Scholar 

  35. Weber A, Fein F, Koch S, Dupont-Gossart AC, Mantion G, Heyd B, Carbonnel F. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm Bowel Dis 2006;12: 1131–5.

    Article  PubMed  Google Scholar 

  36. Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:937–43.

    Article  PubMed  CAS  Google Scholar 

  37. Arts J, D’Haens G, Zeegers M, Van Assche G, Hiele M, D’Hoore A, Penninckx F, Vermeire S, Rutgeerts P. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10:73–8.

    Article  PubMed  Google Scholar 

  38. Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001;44:1436–40.

    Article  PubMed  CAS  Google Scholar 

  39. Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporine for severe ulcerative colitis: a user’s guide. Am J Gastroenterol 1997;92:1424–8.

    PubMed  CAS  Google Scholar 

  40. Cacheux W, Seksik P, Lemann M, Marteau P, Nion-Larmurier I, Afchain P, Daniel F, Beaugerie L, Cosnes J. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008;103:637–42.

    Article  PubMed  CAS  Google Scholar 

  41. Rowe FA, Walker JH, Karp LC et al. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 2000;95:2000–8.

    Article  PubMed  CAS  Google Scholar 

  42. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.44. Gustavsson A, Järnerot G, Hertervig E, et al. A two-year follow up of the Swedish-Danish infliximab/placebo trial in steroid resistant acute ulcerative colitis. Gastroenterology 2007; 132:A146.

    Article  PubMed  CAS  Google Scholar 

  43. Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Alim Pharm Ther 2007;26:411–9.

    Article  CAS  Google Scholar 

  44. Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, et al. Infliximab in severe ulcerative colitis: short term results of different infusion regimens and long term follow up. Alim Pharm Ther 2007;26: 747–56.

    CAS  Google Scholar 

  45. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008;6: 1112–6.

    Article  PubMed  CAS  Google Scholar 

  46. Carbonnel F, Gargouri D, Beaugerie L, Lémann M, Cattan S, Cosnes J, Gendre JP. Predictive factors of outcome of intensive intravenous treatment for severe ulcerative colitis. Alim Pharmacol Ther 2000;14:273–9.

    Article  CAS  Google Scholar 

  47. Matsuoka K, Iwao Y, Mori T, et al. Cytomegalovirus Is Frequently Reactivated and Disappears Without Antiviral Agents in Ulcerative Colitis Patients. Am J Gastroenterol 2007; 102: 331–7.

    Article  PubMed  Google Scholar 

  48. de Saussure P, Lavergne-Slove A, Mazeron MC, Alain S, Matuchansky C, Bouhnik Y. A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease. Aliment Pharmacol Ther 2004;20(11–12):1323–7.

    Article  PubMed  Google Scholar 

  49. Piton G, Dupont-Gossard AC, Weber A, Herbein G, Viennet G, Mantion G, Carbonnel F. Cytomegalovirus infections in patients with steroid-refractory ulcerative colitis treated by oral microemulsion form of cyclosporine. Gastroenterol Clin Biol 2008;32: 460–4.

    PubMed  CAS  Google Scholar 

  50. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006;101:2857–65.

    Article  PubMed  CAS  Google Scholar 

  51. Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5: 339–44.

    Article  PubMed  Google Scholar 

  52. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–10.

    Article  PubMed  CAS  Google Scholar 

  53. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5: 345–51.

    Article  PubMed  Google Scholar 

  54. Stenner JMC, White P, Gould SR, Lim AG. Audit of a management of severe ulcerative colitis in a DGH. Gut 2001; 48 (Suppl1):A87.

    Google Scholar 

  55. Ljung T, Karlen P, Schmidt D, Hellstrom PM, Lapidus A, Janczewska I, Sjoqvist U, Lofberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53: 849–53.

    Article  PubMed  CAS  Google Scholar 

  56. Dolwani S, Hawthorne AB. Mortality caused by inflammatory bowel disease in the UK. A two year survey. Gut 2003;52 (Suppl1):A 12.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Hépatogastroentérologie, centre hospitalier de Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris Sud, France

    F. Carbonnel

Authors
  1. F. Carbonnel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Michel Greff (Président FMC-HGE)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Carbonnel, F. (2009). De la bonne prise en charge des poussées graves de RCH. In: Greff, M. (eds) Post’U FMC-HGE. Springer, Paris. https://doi.org/10.1007/978-2-287-99247-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-99247-6_8

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-99246-9

  • Online ISBN: 978-2-287-99247-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation